Mike Kratky
Stock Analyst at Leerink Partners
(0.64)
# 3,708
Out of 4,829 analysts
27
Total ratings
50%
Success rate
-18.16%
Average return
Main Sectors:
Stocks Rated by Mike Kratky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BBNX Beta Bionics | Initiates: Outperform | $28 | $14.18 | +97.46% | 1 | Feb 24, 2025 | |
| TXG 10x Genomics | Downgrades: Market Perform | $25 → $12 | $9.49 | +26.45% | 2 | Feb 13, 2025 | |
| DXCM DexCom | Maintains: Outperform | $90 → $87 | $85.05 | +2.29% | 2 | Oct 25, 2024 | |
| INSP Inspire Medical Systems | Maintains: Market Perform | $167 → $197 | $156.44 | +25.93% | 2 | Sep 10, 2024 | |
| PEN Penumbra | Initiates: Outperform | $263 | $297.55 | -11.61% | 1 | Sep 3, 2024 | |
| TNDM Tandem Diabetes Care | Upgrades: Outperform | $34 → $45 | $23.45 | +91.90% | 2 | Apr 25, 2024 | |
| NPCE NeuroPace | Initiates: Outperform | $22 | $13.37 | +64.55% | 1 | Jan 30, 2024 | |
| PODD Insulet | Initiates: Outperform | $184 | $316.67 | -41.90% | 1 | Oct 16, 2023 | |
| VCEL Vericel | Initiates: Outperform | $42 | $42.65 | -1.52% | 1 | Oct 16, 2023 | |
| ISRG Intuitive Surgical | Initiates: Outperform | $342 | $561.43 | -39.08% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $75 | $74.80 | +0.27% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $37 | $54.44 | -32.04% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $9 | $11.39 | -20.98% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $325 → $50 | $2.79 | +1,692.11% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $45 | $1.47 | +2,961.22% | 2 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $145 → $315 | $300.76 | +4.73% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $26 → $31 | $32.17 | -3.64% | 2 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $14 | $14.55 | -3.78% | 1 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $40 | $13.12 | +204.88% | 1 | Aug 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $49 → $48 | $0.88 | +5,361.99% | 1 | Aug 11, 2022 |
Beta Bionics
Feb 24, 2025
Initiates: Outperform
Price Target: $28
Current: $14.18
Upside: +97.46%
10x Genomics
Feb 13, 2025
Downgrades: Market Perform
Price Target: $25 → $12
Current: $9.49
Upside: +26.45%
DexCom
Oct 25, 2024
Maintains: Outperform
Price Target: $90 → $87
Current: $85.05
Upside: +2.29%
Inspire Medical Systems
Sep 10, 2024
Maintains: Market Perform
Price Target: $167 → $197
Current: $156.44
Upside: +25.93%
Penumbra
Sep 3, 2024
Initiates: Outperform
Price Target: $263
Current: $297.55
Upside: -11.61%
Tandem Diabetes Care
Apr 25, 2024
Upgrades: Outperform
Price Target: $34 → $45
Current: $23.45
Upside: +91.90%
NeuroPace
Jan 30, 2024
Initiates: Outperform
Price Target: $22
Current: $13.37
Upside: +64.55%
Insulet
Oct 16, 2023
Initiates: Outperform
Price Target: $184
Current: $316.67
Upside: -41.90%
Vericel
Oct 16, 2023
Initiates: Outperform
Price Target: $42
Current: $42.65
Upside: -1.52%
Intuitive Surgical
Oct 16, 2023
Initiates: Outperform
Price Target: $342
Current: $561.43
Upside: -39.08%
Oct 16, 2023
Initiates: Market Perform
Price Target: $75
Current: $74.80
Upside: +0.27%
Oct 16, 2023
Initiates: Outperform
Price Target: $37
Current: $54.44
Upside: -32.04%
Oct 16, 2023
Initiates: Outperform
Price Target: $9
Current: $11.39
Upside: -20.98%
Aug 15, 2023
Downgrades: Market Perform
Price Target: $325 → $50
Current: $2.79
Upside: +1,692.11%
Jan 24, 2023
Maintains: Outperform
Price Target: $33 → $45
Current: $1.47
Upside: +2,961.22%
Dec 20, 2022
Maintains: Outperform
Price Target: $145 → $315
Current: $300.76
Upside: +4.73%
Dec 15, 2022
Maintains: Market Perform
Price Target: $26 → $31
Current: $32.17
Upside: -3.64%
Nov 4, 2022
Maintains: Outperform
Price Target: $12 → $14
Current: $14.55
Upside: -3.78%
Aug 15, 2022
Maintains: Outperform
Price Target: $32 → $40
Current: $13.12
Upside: +204.88%
Aug 11, 2022
Maintains: Outperform
Price Target: $49 → $48
Current: $0.88
Upside: +5,361.99%